Beijing Friendship Hospital

Novel Gelatin Matrix Borayflo Demonstrates Effective Intraoperative Hemostasis in Clinical Trial

6 months ago

• A multicenter, randomized, single-blind trial evaluated Borayflo, a novel hemostatic gelatin matrix, against Surgiflo for intraoperative hemostasis. • Borayflo demonstrated non-inferiority to Surgiflo in achieving hemostasis within 5 minutes, meeting the primary efficacy endpoint. • The study, involving 354 participants across four Chinese hospitals, showed comparable safety profiles between Borayflo and Surgiflo. • Findings suggest Borayflo is a safe and effective alternative for auxiliary hemostasis during surgical procedures.